share_log

Tharimmune | 8-K: Current report

SEC announcement ·  Mar 12 04:22
Summary by Futu AI
On March 7, 2024, Tharimmune, Inc., a Delaware-incorporated biotechnology company, filed a Form 8-K with the Securities and Exchange Commission to report an amendment to its Bylaws. The amendment, approved by the company's board of directors, revises the quorum requirement for stockholder meetings. Previously, a majority of the stockholders needed to be present or represented by proxy for a meeting to proceed. The new amendment lowers this requirement to one-third of the stockholders. The full text of the amendment is included as Exhibit 3.1 in the filing. Tharimmune, which is listed on The Nasdaq Stock Market under the symbol THAR, is classified as an emerging growth company.
On March 7, 2024, Tharimmune, Inc., a Delaware-incorporated biotechnology company, filed a Form 8-K with the Securities and Exchange Commission to report an amendment to its Bylaws. The amendment, approved by the company's board of directors, revises the quorum requirement for stockholder meetings. Previously, a majority of the stockholders needed to be present or represented by proxy for a meeting to proceed. The new amendment lowers this requirement to one-third of the stockholders. The full text of the amendment is included as Exhibit 3.1 in the filing. Tharimmune, which is listed on The Nasdaq Stock Market under the symbol THAR, is classified as an emerging growth company.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.